1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Demographics and clinical features
Descriptive No. (%)
Age groups (per patient, n = 27) (yr) 
    50 and younger 3 (11.1)
    51–64 12 (44.4)
    65–74 9 (33.3)
    75 or older 3 (11.1)
Sex (per patient, n = 27) 
    Female 16 (59.2)
    Male 11 (40.7)
Histology (per patient, n = 27) 
    Breast 9
    Adenocarcinoma 5
    NSCLC 5
    RCC 3
    Colon 2
    Sarcoma 1
    SCC 1
    Small-cell carcinoma 1
Median KPS (per treatment, n = 33) 
    Pre 90
    Post 90
    1 Month 90
Median PFS (per treatment, n = 33) (days) 137
Deceased (per patient, n = 27) 3 (11.1)
Prior SRS (per treatment, n = 33) 25 (75.8)
Completely ablated (per treatment, n = 33) 17 (51.5)
Posttreatment enhancement on postoperative imaging (n = 20) 16 (80)
Preoperative DCE-MRI available (per treatment, n = 33) 33 (100)
Postoperative DCE-MRI available (per treatment, n = 33) 20 (60.6)
One-month DCE-MRI available (per treatment, n = 33) 25 (75.7)
Local recurrence (per treatment, n = 33) 14 (42.4)
Post-LITT chemotherapy (per treatment, n = 33) 16 (48.5)
Note:—NSCLC indicates non-small-cell lung cancer; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; KPS, Karnofsky performance scale; SRS, stereotactic radiosurgery.